A prospective study on lung toxicity in patients treated with gemcitabine and carboplatin: Clinical, radiological and functional assessment

Annals of Oncology

Volumn 15, Issue 8, 2004, Pages 1250-1255

  Dimopoulou, I ^a,d   Efstathiou, E ^b   Samakovli, A ^a   Dafni, U ^c   Moulopoulos, L A ^d   Papadimitriou, C ^b   Lyberopoulos, P ^a   Kastritis, E ^b   Roussos, C ^a   Dimopoulos, M A ^b  

^a EVANGELISMOS HOSPITAL   (Greece)

^b ALEXANDRA HOSPITAL   (Greece)

^c UNIVERSITY OF ATHENS   (Greece)

^d NONE   (Greece)

Author keywords

Carboplatin; Diffusion capacity for carbon monoxide; Dyspnea; Gemcitabine; Lung toxicity; Pulmonary function tests

Indexed keywords

CARBON MONOXIDE; CARBOPLATIN; GEMCITABINE;

ADULT; AGE; AGED; ARTERIAL GAS; ARTICLE; BILIARY TRACT CANCER; BLADDER CARCINOMA; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; FUNCTIONAL ASSESSMENT; GAS DIFFUSION; GENDER; HUMAN; KIDNEY CANCER; LIVER CANCER; LUNG DIFFUSION CAPACITY; LUNG FIBROSIS; LUNG FUNCTION; LUNG FUNCTION TEST; LUNG TOXICITY; MALE; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; RADIODIAGNOSIS; RISK FACTOR; STATISTICAL ANALYSIS; SYMPTOM; TOTAL LUNG CAPACITY;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DEOXYCYTIDINE; FEMALE; HUMANS; LUNG; MALE; MIDDLE AGED; NEOPLASMS; PROSPECTIVE STUDIES; PULMONARY DIFFUSING CAPACITY;

EID: 4444313468     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh311     Document Type: Article

References (30)

1. Carmichael J. The role of gemcitabine in the treatment of other tumours. Br J Cancer 1998; 78 (Suppl 3): 21-25.
2. Tonato M, Mosconi AM, Martin C. Safety profile of gemcitabine. Anticancer Drugs 1995; 6 (Suppl 6): 27-32.
3. Pavlakis N, Bell DR, Millward MJ, Levi JA. Fatal pulmonary toxicity resulting from treatment with gemcitabine. Cancer 1997; 80: 286-291.
4. Sauer-Heilborn A, Kath R, Schneider CP, Hoffken K. Severe non-haematological toxicity after treatment with gemcitabine. J Cancer Res Clin Oncol 1999; 125: 637-640.
5. Dunsford ML, Mead GM, Bateman AC et al. Severe pulmonary toxicity in patients treated with a combination of docetaxel and gemcitabine for metastatic transitional cell carcinoma. Ann Oncol 1999; 10: 943-947.
6. Boiselle PM, Morrin MM, Huberman MS. Gemcitabine pulmonary toxicity: CT features. J Comput Assist Tomogr 2000; 24: 977-980.
7. Joerger M, Gunz A, Speich R, Pestalozzi BC. Gemcitabine-related pulmonary toxicity. Swiss Med Wkly 2002; 132: 17-20.
8. Maas KW, van der Lee I, Bolt K et al. Lung function changes and pulmonary complications in patients with stage III non-small cell lung cancer treated with gemcitabine/cisplatin as part of combined modality treatment. Lung Cancer 2003; 41: 345-351.
9. Gupta N, Ahmed I, Steinberg H et al. Gemcitabine-induced pulmonary toxicity. Case report and review of the literature. Am J Clin Oncol 2002; 25: 96-100.
10. Roychowdhury DF, Cassidy CA, Peterson P, Arning M. A report on serious pulmonary toxicity associated with gemcitabine-based therapy. Invest New Drugs 2002; 20: 311-315.
11. Zatloukal P, Kanitz E, Magyar P et al. Gemcitabine in locally advanced and metastatic non-small cell lung cancer: the Central European phase II study. Lung Cancer 1998; 22: 243-250.
12. Hoang T, Kim K, Jaslowski A et al. Phase II study of second-line gemcitabine in sensitive or refractory small cell lung cancer. Lung Cancer 2003; 42: 97-102.
13. Chen YM, Perng RP, Yang KY et al. A multicenter phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (stage IIIB/IV) non-small cell lung cancer. Chest 2000; 117: 1583-1589.
14. Bhatia S, Hanna N, Ansari R et al. A phase II study of weekly gemcitabine and paclitaxel in patients with previously untreated stage IIIb and IV non-small cell lung cancer. Lung Cancer 2002; 38: 73-77.
15. Nowak AK, Byrne MJ, Williamson R et al. A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer 2002; 87: 491-496.
16. Blackstock AW, Lesser GJ, Fletcher-Steede J et al. Phase I study of twice-weekly gemcitabine and concurrent thoracic radiation for patients with locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2001; 51: 1281-1289.
17. Cooper JAD, White DA, Matthay RA. Drug-induced pulmonary disease. Part 1: cytotoxic drugs. Am Rev Respir Dis 1986; 133: 321-340.
18. American Thoracic Society. Single-breath carbon monoxide diffusion capacity (transfer factor). Recommendations for a standard technique-1995 update. Am J Respir Crit Care Med 1995; 152: 2185-2198.
19. American Thoracic Society. Evaluation of impairment/disability secondary to respiratory disorders. Am Rev Respir Dis 1986; 133: 1205-1209.
20. Hughes JMB. Presentation of pulmonary function test to the clinician. In Hughes JMB, Pride NB (eds): Lung Function Tests: Physiological Principles and Clinical Applications, 1st edition. London: W.B. Saunders 1999; 287-295.
21. Castro M, Veeder MH, Mailliard JA et al. A prospective study of pulmonary function in patients receiving mitomycin. Chest 1996; 109: 939-944.
22. Cottin V, Tebib J, Massonnet B et al. Pulmonary function in patients receiving long-term low-dose methotrexate. Chest 1996; 109: 933-938.
23. Dimopoulou I, Galani H, Dafni U et al. A prospective study of pulmonary function in patients treated with paclitaxel and carboplatin. Cancer 2002; 94: 452-458.
24. Takada M, Negoro S, Kudo S et al. Activity of gemcitabine in non-small-cell lung cancer: results of the Japan gemcitabine group (A) phase II study. Cancer Chemother Pharmacol 1998; 41: 217-222.
25. Sorensen JB, Bergman B, Nielsen AL et al. Phase II study of gemcitabine and vindesine in patients with previous untreated non-resectable non-small-cell lung cancer. Br J Cancer 1999; 79: 875-881.
26. Carron PL, Cousin L, Caps T et al. Gemcitabine-associated diffuse alveolar hemorrhage. Intensive Care Med 2001; 27: 1554.
27. Vansteenkiste JF, Bomans P, Verbeken EK et al. Fatal pulmonary veno-occlusive disease possibly related to gemcitabine. Lung Cancer 2001; 31: 83-85.
28. Vander Els NJ, Miller V et al. Successful treatment of gemcitabine toxicity with a brief course of oral corticosteroid therapy. Chest 1998; 114: 1779-1781.
29. Markman M, Kennedy A, Webster K et al. Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol 1999; 17: 1141-1145.
30. Groen HJM, Van der Mark TW, Van der Leest AHD et al. Pulmonary function changes in lung-cancer patients treated with radiation with or without carboplatin. Am J Respir Crit Care Med 1995; 152: 2044-2048.